Systemic application of IL-33 for cancer immunoprevention and immunotherapy - PubMed
3 days ago
- #Immunotherapy
- #Tumor Immunology
- #IL-33
- Systemic IL-33 treatment enhances prophylactic tumor vaccine effects and inhibits mouse solid tumor progression.
- IL-33 reshapes the tumor immune microenvironment, increasing ST2+ Treg cells, but anti-tumor effects depend on Treg ST2, unlike endogenous IL-33/ST2.
- IL-33 reprograms Treg cells towards a cytotoxic, inflammatory phenotype in mice, with no evidence that endogenous IL-33 promotes tumor growth.
- Findings support IL-33 use in cancer immunoprevention and immunotherapy via a Treg ST2-dependent mechanism.